' Practice Changing ' : Ruxolitinib as Second-Line in Chronic GVHD ' Practice Changing ' : Ruxolitinib as Second-Line in Chronic GVHD

A significant advantage was observed for ruxolitinib, as compared with standard therapy, for the treatment of chronic graft-versus-host disease (GVHD).Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news